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Abstract: Patients with advanced liver cirrhosis are at risk of malnutrition and nutrition-associated
complications. Significant ascites, a frequent finding in these patients, has an especially negative
impact on oral nutrition. A negative caloric and protein balance can further deteriorate the already
impaired synthetic function of the cirrhotic liver. An important factor in this situation is the
diminished capacity of glycogen production and storage in the cirrhotic liver and, consequently,
a reduced tolerability for fasting episodes. These episodes are frequently observed in hospitalized
patients, e.g., while waiting for investigations, interventions or surgery. A comprehensive work-up
of patients with advanced liver cirrhosis should include not only a thorough assessment regarding
nutritional deficits, but also a muscularity analysis to identify patients with sarcopenia. The overall
nutritional treatment goal is to cover caloric deficits and assure a sufficiently high protein intake.
Furthermore, vitamin and micronutrient deficiencies should be identified and corrective measures
implemented where required. Ideally, optimal nutrition management can not only prevent the
progression of malnutrition and sarcopenia in patients with advanced liver cirrhosis, but positively
influence the evolution of the liver disease.
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1. Introduction
Liver cirrhosis is a common end stage of several liver diseases. The most prevalent aetiologies are
chronic hepatitis B virus (HBV) and hepatitis C virus (HCV) infection, alcoholism, and nonalcoholic
steatohepatitis [1]. As, with the introduction of direct acting antiviral therapy, HCV and HCV-related
complications are rapidly declining, nonalcoholic steatohepatitis is now a growing burden of cirrhosis.
In patients with advanced liver cirrhosis, malnutrition and sarcopenia are not only related to
alterations in the nutritional behavior, but also to changes in the GI-tract, the liver and the muscle.
An increased protein loss, via the GI-tract, the kidneys or frequent paracenteses, can further aggravate
the situation.
Patients with chronic advanced liver disease suffer from increased fatigue, nausea, bloating, and
anorexia, which can result in a reduced food intake. In the presence of clinically relevant ascites,
mechanical effects may further compromise nutrition by compression of the stomach, resulting in early
satiety [2]. Inadequate appetite regulation and energy expenditure may be related to an elevation
in bound leptin in patients with cirrhosis. Whereas free leptin correlates with fat mass in cirrhotic
patients as well as in healthy controls, bound leptin was positively correlated with energy expenditure
in patients with cirrhosis [3]. Increased serum concentrations of bound leptin could be associated
with wasting in patients with liver cirrhosis, as has been shown in patients with symptomatic human
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immunodeficiency virus [4]. Furthermore, leptin is also a known contributor to fibrinogenesis in
chronic liver disease [5]. Small bowel transit time is correlated with the severity of liver disease, and
patients with decompensated cirrhosis or spontaneous bacterial peritonitis in the context of ascites
have a slower transit time [6].
In patients with alcoholic cirrhosis, anorexia and irregular unbalanced nutrition uptake are
common, and energy supply may be achieved through the consumption of alcohol rather than by a
balanced food intake [7]. A low socioeconomic status is an additional risk factor for poor nutrition [2].
Dietary restrictions, e.g., an untasty, sodium-reduced diet, inadequate protein supply, or taste
alterations, may further compromise the nutrition of patients with cirrhosis [2].
For the assessment of malnutrition and sarcopenia different tools, comprising clinical and
laboratory parameters, physical assessments, image analysis and anthropometric measurements, are
available. Clinical bedside assessments are easy to perform and inexpensive, but may lack precision in
patients with advanced cirrhosis, especially if significant ascites is present. In contrast, muscularity
analysis on cross-sectional images is precise but technically demanding and may require special
software tools and trained personnel.
2. Comprehensive Assessment of Patients with Advanced Liver Cirrhosis
2.1. Malnutrition
To assess the nutritional status of patients, the subjective global assessment (SGA) is a
well-established and widely used bedside tool. Patients are assigned to one of the three different risk
categories: A (well nourished), B (mildly/moderately malnourished), and C (severely malnourished),
based on five items that can be derived from the patient’s history and three items that are based on clinical
examinations. SGA is an independent predictor of outcome in liver transplant recipients [8,9]. However,
especially in decompensated patients with ascites or peripheral fluid accumulation, the performance
of SGA is limited [10].
2.2. Liver Function
Unfortunately, a simple test to assess the main dimensions of liver function (synthetic function,
metabolic capacity and excretion function) does not exist. In the context of malnutrition, the synthetic
function of the liver is of special interest. Albumin levels are frequently tested in patients with liver
disease, and albumin is part of the widely used Child–Pugh–Turcotte (CPT) score to determine the stage
of liver disease [11]. However, albumin levels do not solely reflect endogenous albumin production,
but may also be low due to infection/inflammation, or an increased albumin loss or high in the case
of albumin substitution, for instance, in patients that frequently require large volume paracenteses.
In recent years, functional aspects, like the binding of lipopolisaccharides or other bacterial products
and qualitative alterations (oxidation and glycation) of albumin, have been investigated in more detail.
However, to date, it is not clear what the impact of these findings is [12].
Prealbumin (transthyretin) is an alternative parameter to assess the synthetic function in patients
with liver cirrhosis. Prealbumin plasma levels decrease progressively from CPT stage A to C and
correlate with galactose elimination capacity, a test to assess functional liver capacity [13]. A major
advantage of this parameter compared to albumin is the fact that it is not influenced by exogenous
albumin administration, a frequent treatment in patients with decompensated liver cirrhosis. The
addition of prealbumin to the Model for End-stage Liver Disease (MELD) score improved outcome
prediction in patients with decompensated liver cirrhosis [14], and prealbumin was a predictive
factor regarding postoperative liver insufficiency and survival in CPT A patients with hepatocellular
carcinoma-related surgery [15–17]. In clinical practice, prealbumin is an inexpensive and easy to
determine functional liver parameter that helps to assess the synthetic liver function in cirrhotic patients.
However, compared to albumin, the available evidence is limited in patients with liver cirrhosis.
Prothrombin time (PT) is the second parameter reflecting synthetic liver function that is an integral
part of the CPT score (all coagulation factors, with the exception of factor VIII, are produced in the
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liver). However, production of coagulation factors may be preserved even in advanced cirrhosis and
patients may still present with a normal or only slightly decreased PT in this situation. In contrast,
patients with acute liver failure frequently have markedly decreased PT values.
2.3. Sarcopenia
Although sarcopenia is usually a visual diagnosis in malnourished patients with cirrhosis,
diagnosis may be more challenging in obese patients, e.g., in patients with non-alcoholic fatty liver
disease (NAFLD). To obtain an objective measure of sarcopenia, a quantitative analysis of the patient’s
muscularity should be performed.
The most-validated method to date is the muscle assessment on cross-sectional CT or MR images.
Several methods have been proposed, e.g., area of the psoas muscle at the level of the 4th lumbar
vertebra without and with normalization by height [18,19], the skeletal muscles index at the level of
the 3rd lumbar vertebra (SMI) [19,20], or transversal psoas thickness at the level of the umbilicus [21].
Importantly, by using the SMI with the gender specific cut-offs (42 cm2/m2 for women and 50 cm2/m2
for men), muscle wasting was not limited to underweight patients, but could be detected in cirrhotic
patients with a normal or even elevated BMI [20]. Regarding mortality risk in patients with cirrhosis, the
skeletal muscle index (SMI) seems to be superior to the psoas index, especially in men with cirrhosis [22].
Special attention is required for patients with advanced liver cirrhosis who have a BMI >25 kg/m2.
Sarcopenia in obese patients is frequently overlooked, since it is less expected than in underweight or
normal-weight patients with malnutrition. It is important to note that sarcopenic obesity, as well as
myosteatosis, characterized by an increased proportion of muscular fat, are independent risk factors
regarding long-term mortality [23].
Apart from simple measurements, like psoas muscle diameter, the assessment of cross-sectional
image analysis is technically demanding and may require special image analysis software and trained
personnel. Therefore, image analysis is mainly used in the context of clinical research projects.
In clinical practice, bio impedance analysis (BIA), dual-energy X-ray absorptiometry (DEXA) and
anthropometric measurements are easier to perform. However, DEXA and BIA results may be altered
in patients with significant ascites and general fluid overload, limiting their use in decompensated
patients [24]. Restricting DEXA to the upper limb lean mass, and therefore excluding the body parts
that are most prone to fluid overload, resulted in a good sarcopenia-related prediction of mortality in
men with advanced cirrhosis [25]. Mid-arm muscle circumference (MAMC) measurement is easy to
perform, but its relevance in clinical practice is limited [26].
Unfortunately, the most frequently used scores in patients with cirrhosis, CPT and MELD score [27],
do not contain specific information about the nutritional status of a given patient. Therefore, new scores
have been developed and evaluated, with a focus on outcome, in patients awaiting liver transplantation.
The MELD-psoas score includes transversal psoas muscle thickness normalized by height at the level
of the umbilicus. This score was significantly associated with mortality, especially in patients with
refractory ascites [21].
The addition of the skeletal muscle index (SMI), as a measure of sarcopenia, to the MELD score
resulted in an improved prediction of mortality in patients with cirrhosis [20,28]. Especially in low
MELD patients on a liver transplant list, the inclusion of sarcopenia resulted in a better association
with mortality [21].
2.4. Deficiencies of Vitamins and Micronutrients
2.4.1. Vitamin D
Vitamin D is synthesized in the skin from 7-dehydrocholesterol. An alternative source is
food-derived vitamin D that is absorbed in the gastrointestinal tract with the help of bile acids. Vitamin
D subsequently undergoes two hydroxylation steps, 25-hydroxylation in the liver and 1α-hydroxylation
in the kidney. Whereas vitamin D is considered biologically inactive, 25-hydroxy(OH)-vitamin D is
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the main circulating metabolite. Conversion to 1,25-dihydroxy-vitamin D in the kidney increases the
affinity for the vitamin D receptor (VDR).
The main purpose of vitamin D is the regulation of mineral and bone homeostasis. However,
several other functions in different tissues (kidney, intestine, skin, immune cells and non-parenchymal
hepatic cells) are known, too [29].
Vitamin D deficiency is common in liver cirrhosis. Whereas liver function correlates with vitamin
D deficiency, aetiology of the liver disease seems to be of minor importance [30,31]. Decreased vitamin
D levels are associated with an unfavorable outcome in patients with chronic advanced liver disease.
The relative risk for hepatic decompensation and for mortality was 6.37 (95% confidence interval (CI)
1.75–23.2) and 4.31 (95% CI 1.38–13.5), respectively, for patients in the lowest OH-vitamin D level
group, compared to patients in the highest OH-vitamin D level group [31].
2.4.2. Vitamin A
The liver is the organ where most (>90%) of the body vitamin A is stored. Plasma contains only a
fraction (1%) of the total amount of vitamin A. While normal and high vitamin A concentrations do
not show a linear correlation with liver vitamin A reserves, low retinol plasma levels do correlate [32].
In patients with chronic liver disease, vitamin A levels are frequently reduced, and the concentration
progressively decreases with the progression of liver disease. Importantly, patients with hepatocellular
carcinoma have the lowest levels, independent of the stage of liver disease [33]. While, in patients
with CPT A cirrhosis, severe deficiency was absent, 52.8% of Child–Pugh C patients presented with
a severe vitamin A deficiency (<0.35 µmol/L) [34]. It is important to note that chronic high dose
supplementation over a period of several years has been associated with relevant liver damage [35].
2.4.3. Zinc
Zinc deficiency is a common finding in patients with advanced chronic liver disease. Reasons for
low zinc levels are inadequate dietary intake and an increased zinc loss in the urine that is related to
severe muscle catabolism, diuretic therapy in patients with cirrhosis and ascites [36], alcohol-induced
impaired absorption, and changes in the protein and amino acid metabolism. Furthermore, endotoxins
and cytokines (IL6) may play a role [37].
Since the liver is the key organ in the metabolism of zinc, liver disease can affect zinc levels and,
vice versa, zinc deficiency can affect the liver. Reduced zinc levels can have a negative impact on
several liver functions and impair the regeneration capacity of the liver. However, independent of
the stage of cirrhosis, zinc stores in in liver, bone and muscle can be replenished over the course of
six or more months [37]. In patients with cirrhosis, supplementation of zinc in combination with
branched-chain amino acids (BCAA) for six months with [38] and without [39] hepatic encephalopathy
has demonstrated a positive effect on blood ammonia levels. However, an increase in albumin could
be demonstrated only in one of the two studies [38].
2.4.4. Selenium
The essential micronutrient selenium is incorporated in at least 25 selenoproteins. Deficiency
of selenium can be found in some patients with advanced chronic liver disease. In addition to a
nutritional deficit, reduced selenium levels may reflect an impaired metabolism of selenomethionine
to selenide in the liver. In a study by Burk et al., selenoprotein P, a protein that is mainly formed in the
liver and that transports selenium to extrahepatic tissues, was reduced in parallel with the severity of
the liver disease [40].
2.5. Bone Disease
Osteopenia and osteoporosis are common findings in patients with cirrhosis, with a prevalence of
up to 68% for osteopenia and a range from 11% to 55% for osteoporosis [41]. Consequently, fractures
are common in patients with chronic liver disease, and occur in up to 40% of patients with cirrhosis [42].
J. Clin. Med. 2019, 8, 1926 5 of 11
The pathophysiology is complex and, in addition to an altered vitamin D and calcium metabolism, other
factors may be important. Hypogonadism is associated with an increased osteoclast activity, leading
to accelerated bone loss. An excess of unconjugated bilirubin negatively affects the differentiation
of primary osteoblasts into their primary function. Chronic glucocorticoid therapy in patients with
autoimmune hepatitis is associated with osteoporosis, and environmental factors, such as chronic
alcohol consumption, smoking, low BMI, sedentary lifestyle and poor nutrition have an additional
negative effect on bone turnover [43].
Screening for osteopenia and osteoporosis should be considered in all patients suffering from liver
cirrhosis, and be part of the standard procedure in patients that are evaluated for liver transplantation.
A timely diagnosis is important to prevent fractures as typical osteoporosis-related complications. Bone
mineral density screening should be repeated on a yearly basis in patients with cholestatic liver disease
and/or multiple risk factors and every two to three years in other patients with liver cirrhosis [41].
3. Therapeutic Approach to Treat Nutritional Deficits
3.1. Caloric, Protein and Lipid Supplementation
In patients with advanced cirrhosis, nutrition is of paramount importance. A nutritional assessment
should be performed on a regular basis and corrective measures implemented as soon as a deficit
is observed. If available, a clinical nutrition specialist should perform the nutritional assessment.
The aim is to identify daily deficits and to define daily nutritional requirements. This assessment
should include caloric and protein intake as well as vitamins and micronutrients.
In patients with cirrhosis, a daily intake of 30–35 kcal and of 1.2 to 1.5 g protein per kg body
weight (BW) is recommended [44,45]. In obese patients with liver cirrhosis, a moderately hypocaloric
diet (−500–800 kcal/d), respectively a reduced daily caloric intake of 20–25 kcal/kg BW, should be
combined with an increase in protein intake (>1.5 g, up to 2.5 g/kg BW) [44–46], Table 1.
Regarding lipids, no specific recommendations are provided in the guidelines for patients with
liver cirrhosis [44,45]. Compared to the glucose and protein metabolism, alterations in the lipid
metabolism seem to be of minor importance in patients with liver cirrhosis. This is illustrated by the
finding that the elimination of lipid emulsions containing long-chain or long-chain and medium-chain
triglycerides, and the release of free fatty acids thereof were not altered in patients with chronic hepatic
failure compared to healthy controls [47,48].
Table 1. Nutrition management in patients with advanced liver cirrhosis.
Cirrhosis with Malnutrition Cirrhosis with Sarcopenic Obesity
Caloric intake 30–35 kcal/kg BW 20–25 kcal/kg BW
Protein intake 1.2 to 1.5 g/kg BW >1.5 g, up to 2.5 g/kg BW
Lipid intake No specific recommendation No specific recommendation
Vitamins
Vitamin A * Supplement if decreased Supplement if decreased
Vitamin D Supplement if decreased Supplement if decreased
Micronutrients
Zinc Supplement if decreased Supplement if decreased
Selenium Supplement if decreased Supplement if decreased
BW: body weight. * avoid oversubstitution.
Ideally, the nutritional goals can be achieved by regular meals, if required, by reducing the size
and increasing the frequency of meals. A late evening snack is recommended to compensate for the
reduced glycogen production and storage, and to prevent muscle proteolysis in patients with advanced
cirrhosis [49]. The snack should comprise at least 50 g of complex carbohydrates [46]. If required,
protein-enriched oral drinks can be added.
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In patients that cannot achieve the nutritional goals with oral substitution, placement of an enteral
tube should be considered. The presence of non-bleeding esophageal varices is not a contraindication
for enteral tube feeding [44,45]. In contrast, a percutaneous enteral gastrostomy (PEG) is associated
with an elevated risk of complications, especially bleeding, and is therefore not recommended in
patients with chronic advanced liver disease [44,45].
Periods of prolonged fasting should be avoided whenever possible. Risk situations are prolonged
waiting time for interventions or surgery, and situations in which a patient is temporarily not able to
maintain oral nutrition, e.g., during a stay in the intensive care unit. If oral or enteral feeding is not
possible, parenteral nutrition should be considered early [44,45], Figure 1.
J. Clin. Med. 2019, 8 FOR PEER REVIEW  6 
In patients that cannot achieve the nutritional goals with oral substitution, placement of an 
enteral tube should be considered. The presence of non-bleeding esophageal varices is not a 
contraindication for enteral tube feeding [44,45]. In contrast, a percutaneous enteral gastrostomy 
(PEG) is associated with an elevated risk of complications, especially bleeding, and is therefore not 
recommended in patients with chronic advanced liver disease [44,45]. 
Periods of prolonged fasting should be avoided whenever possible. Risk situations are 
prolonged waiting time for interventions or surgery, and situations in which a patient is temporarily 
not able to maintain oral nutrition, e.g., during a stay in the intensive care unit. If oral or enteral 
feeding is not possible, parenteral nutrition should be considered early [44,45], Figure 1. 
 
Figure 1. Nutrition management in malnourished patients with liver cirrhosis. * Non-bleeding 
esophageal varices are not a contraindication for enteral tube feeding, +if enteral nutrition is 
insufficient, ++if enteral nutrition is not possible. 
In patients with liver cirrhosis, restriction of protein intake is not indicated [44,45], since this 
promotes muscle proteolysis [50] and increased the risk of mortality on the waiting list for liver 
transplants [51]. Intolerance of mixed proteins with consecutive development of hepatic 
encephalopathy is very rare. In this specific situation, a diet with vegetable proteins may be beneficial 
[44], since vegetable proteins are rich in BCAA compared to animal proteins, and BCAA remove one 
mole of ammonia per mole of BCAA [52]. Alternatively, BCAA or leucine-enriched BCAA 
supplementation can be considered, the latter showing a stimulatory, and therefore beneficial, effect 
on mTORC1 in the skeletal muscle of patients with alcoholic liver cirrhosis [53]. After an episode of 
overt hepatic encephalopathy, BCAA supplementation improved muscle mass and minimal HE, but 
did not decrease recurrence of overt hepatic encephalopathy [45,54]. 
3.2. Albumin 
From a nutritionist point of view, there is no indication for the substitution of albumin in patients 
with liver cirrhosis. However, albumin is used in patients with refractory ascites to prevent the 
circulatory dysfunction syndrome following paracentesis, in the setting of hepatorenal syndrome and 
in case of infection, especially spontaneous bacterial peritonitis (SBP) [55]. Whether long-term 
albumin infusions have a significant effect on morbidity and mortality in patients with advanced 
liver cirrhosis is currently being debated. In the ANSWER study, patients receiving albumin on a 
weekly basis had a lower mortality and complication rate than patients in the placebo group [56]. 
However, there were some concerns regarding the methodology of this trial (open label study, 
different management of the two treatment arms). No effect on the complication rate in patients with 
cirrhosis awaiting liver transplantation was found in the MACHT trial, that investigated the addition 
of midodrine and albumin to the standard of care treatment [57]. 
3.3. Vitamins and Micronutrients 
Figure 1. Nutrition management in malnourished patients with liver cirrhosis. * Non-bleeding
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In patients with liver cirrhosis, restriction of protein intake is not indicated [44,45], since this
promotes muscle proteolysis [50] and increased the risk of mortality on the waiting list for liver
transplants [51]. Intolerance of mixed proteins with consecutive development of hepatic encephalopathy
is very rare. In this specific situation, a diet with vegetable proteins may be beneficial [44], since
vegetable proteins are rich in BCAA compared to animal proteins, and BCAA remove one mole of
ammonia per mole of BCAA [52]. Alternatively, BCAA or leucine-enriched BCAA supplementation
can be considered, the latter showing a stimulatory, and therefore beneficial, effect on mTORC1 in
the skeletal muscle of patients with alcoholic liver cirrhosis [53]. After an episode of overt hepatic
encephalopathy, BCAA supplementation improved muscle mass and minimal HE, but did not decrease
recurrence of overt hepatic encephalopathy [45,54].
3.2. Albumin
From a nutritionist point of view, there is no indication for the substitution of albumin in patients
with liver cirrhosis. However, albumin is used in patients with refractory ascites to prevent the
circulatory dysfunction syndrome following paracentesis, in the setting of hepatorenal syndrome and
in case of infection, especially spontaneous bacterial peritonitis (SBP) [55]. Whether long-term albumin
infusions have a significant effect on morbidity and mortality in patients with advanced liver cirrhosis
is currently being debated. In the ANSWER study, patients receiving albumin on a weekly basis
had a lower mortality and complication rate than patients in the placebo group [56]. However, there
ere some concerns regarding the methodology of this trial (open label study, different management
of the two treatment arms). No effect on the complication rate in patients with cirrhosis awaiting
liver transplantation was found in the MACHT trial, that investigated the addition of midodrine and
albumin to the standard of care treatment [57].
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3.3. Vitamins and Micronutrients
Vitamin D has a broad impact not only on bone metabolism, but also on several hepatic cells and
functions. Therefore, supplementation in case of reduced levels (<20 ng/mL) is indicated to prevent
the risk of fractures that is increased in patients with cirrhosis [42], and to maintain Vitamin D related
liver functions. A level of >30 ng/mL should be the therapeutic target [58,59].
For vitamin A, there is no generally accepted opinion regarding supplementation. Due to the
negative effect on the liver in case of long-term high-dose substitution (>40,000 IU per day), some
authors recommend against supplementation of vitamin A [34]. Taking into account the linear
relationship between low serum retinol and vitamin A storage, and the association of HCC with very
low vitamin A levels [33], low level substitution for a limited period of time in case of reduced vitamin
A levels can be considered.
Zinc deficiency is frequent in patients with chronic liver disease and has been associated with
insulin resistance, hepatic steatosis, iron overload and hepatic encephalopathy. Consequently, zinc
levels should be measured in patients with cirrhosis and zinc supplemented in case of reduced
levels [37,60].
Since cirrhosis causes functional selenium deficit in some patients, and, taking into account that
the prevalence of selenium deficit rises with the severity of cirrhosis, supplementation in case of a
confirmed deficit can be considered. However, to date, data regarding positive or negative effects
of selenium substitution in patients with advanced liver cirrhosis are missing and, consequently, no
general recommendation is possible. If selenium is supplemented, selenite and not selenomethionine
should be prescribed, due to the altered metabolism in patients with cirrhosis [61].
3.4. General Management
Patients with malnutrition and sarcopenia should be followed on a regular basis by a clinical
nutrition specialist, and nutritional status as well as measures to correct malnutrition and sarcopenia
should be periodically reassessed. Furthermore, nutritional aspects should be integrated in the
assessment and the clinical decision-making process by the multidisciplinary medical team treating
patients with advanced chronic liver disease.
4. Conclusions
Patients with advanced liver cirrhosis are prone to malnutrition. Reasons for malnutrition are a
reduced intake of food and especially proteins, a decreased synthetic function of the liver, impaired
glycogen production and storage, proteolysis in the muscle, and loss of proteins via paracenteses, the
kidneys or the GI tract.
A comprehensive management of patients with advanced chronic liver disease should aim at the
identification of malnutrition in general and selective nutritional deficits in particular. Due to ascites
and general fluid overload, body weight and body mass index may be misleading in cirrhotic patients,
and a more in-depth analysis of body composition and function is indicated. SGA is an easy to perform
nutritional assessment in patients with liver cirrhosis. However, in overweight and obese patients, its
performance is limited, due to a weak concordance with sarcopenia [10].
Sarcopenia, a common complication in patients with advanced liver cirrhosis, is at least partially
the consequence of malnutrition. Ideally, it can be diagnosed from cross-sectional abdominal images.
Sarcopenic obese patients need special attention, since nutritional and muscularity deficits may
be overlooked.
Treatment of patients with advanced liver cirrhosis should be comprehensive and address
the individual patients’ caloric and protein requirements, as well as the correction of vitamin and
micronutrient deficits. Whether continuous administration of albumin is helpful in malnourished
cirrhotic patients is currently not clear, since study results are discordant.
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There is certainly a need for more randomized studies, to better assess the effect of a comprehensive
nutritional management on mortality and morbidity, and, in particular, on the evolution of sarcopenia
and other cirrhosis-associated complications.
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